Clinical trials: Neuroepithelial Tumor
Glioma, Malignant, High Grade Glioma
Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
The primary goal of this Phase 1 study is to determine if a new investigational drug, OS2966, when delivered directly to the brain of adult participants with recurrent/progressive high-grade glioma (HGG) is safe and well…
- Conditions
- Glioma, Malignant, High Grade Glioma, Glioblastoma, Glioblastoma Multiforme
- Trial name
- NCT04608812
- Testing
- OS2966, Gadoteridol
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- OncoSynergy, Inc.
Newly Diagnosed Glioblastoma
New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study
This phase I/II trial evaluates the safety and the immunological efficacy of a cancer vaccine against 2 glioma-associated antigens in newly-diagnosed glioblastomas.
- Trial name
- NAVIG-1 (NCT06622434)
- Testing
- immunization
- Where
- 3 sites in France
- Volunteers
- 35 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Glioblastoma
Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma
This clinical trial measures the amount and effect of lidocaine injected into patients with glioblastoma while they are undergoing surgical removal of their brain tumors.
- Trial name
- NCT04716699
- Testing
- Biospecimen Collection, Lidocaine, Resection
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, Davis
Recurrent Glioblastoma
OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
In this study we are evaluating the safety and feasibility of the triple combination (TTFields, MLA, pembrolizumab) in adult patients diagnosed with recurrent or progressive glioblastoma (GBM) WHO Grade IV, IDH wild type or…
- Trial name
- OPTIMUS PRIME (NCT06558214)
- Testing
- Pembrolizumab, Optune GIO®, NeuroBlate®
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Brain and Central Nervous System Tumors
Radiation Therapy or Temozolomide in Treating Patients With Gliomas
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00182819
- Testing
- temozolomide, radiation therapy
- Where
- 89 sites in Australia, Austria and 17 more
- Volunteers
- 709 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Glioblastoma
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
This is an open-label, multicenter, phase II study to evaluate the safety, efficacy, and pharmacokinetic characteristics of BL-B01D1 for Injection in patients with recurrent glioblastoma.
- Trial name
- NCT06598787
- Testing
- BL-B01D1 for Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Glioma
Image Guided Therapy in the Treatment of Gliomas
RATIONALE: New imaging techniques using magnetic resonance imaging give better tumor definition, thus may lead to better tumor targeting and avoid damaging critical parts of normal brain.
- Trial name
- NCT01263821
- Testing
- Diffusion-weighted magnetic resonance imaging, Perfusion-weighted magnetic resonance imaging, Functional magnetic resonance imaging
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- NYU Langone Health
Glioblastoma Multiforme
Sonodynamic Therapy With ExAblate System in Glioblastoma Patients
The goal of this prospective, non-randomized, single-arm study is to evaluate the safety and feasibility of sonodynamic therapy with 5-aminolevulinic acid in patients with newly diagnosed cerebral glioblastomas using the ExAblate…
- Trial name
- Sonic ALA (NCT04845919)
- Testing
- 5-Aminolevulinic Acid
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Gliomas
C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression
This study will investigate how well Carbon Acetate PET/CT imaging helps to correctly identify recurrent tumor versus post treatment effects (radionecrosis) in patients with previously treated high grade brain gliomas.
- Trial name
- NCT01961934
- Testing
- Sodium Acetate C11 PET/CT Imaging
- Where
- United States
- Sponsor
- Phoenix Molecular Imaging
Glioma
MRS of Glioma Genomics
In France, about 5000 new people with a primary malignant brain tumor are diagnosed each year. The most common primary tumors are gliomas, originating from glial cells (astrocytomas and oligodendrogliomas).
- Trial name
- GLIOMRS (NCT05700071)
- Testing
- MRI
- Where
- 2 sites in France
- Volunteers
- 110 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Retinoblastoma, Secondary Primary Malignancies After Retinoblastoma
New Strategies to Detect Cancers in Carriers of Mutations in RB1
Rationale: Individuals with a cancer predisposition due to a mutation in the paradigm tumor suppressor gene RB1, have a high risk to develop the childhood cancer retinoblastoma (Rb).
- Trial name
- NIRBTEST (NCT04164134)
- Testing
- blood draw
- Where
- 3 sites in France, Germany and 1 more
- Volunteers
- 378 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Glioblastoma Multiforme
mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme
The standard or usual treatment for this disease is standard chemotherapy alone. AZD2014 is a new type of drug for glioblastoma multiforme. In the laboratory it has been shown to slow the growth of glioblastoma multiforme.
- Trial name
- NCT02619864
- Testing
- AZD2014
- Where
- 4 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Canadian Cancer Trials Group
Neuroblastoma
SF1126 for Patients With Relapsed or Refractory Neuroblastoma
SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active moiety (consisting of LY294002) linked to an RGDS tetrapeptide that targets the active agent to integrin expressing tissues.
- Trial name
- NCT02337309
- Testing
- SF1126
- Where
- 11 sites in United States
- Volunteers
- 4 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Glioblastoma Multiforme (GBM), Glioblastoma
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly…
- Conditions
- Glioblastoma Multiforme (GBM), Glioblastoma, Glioma of Brain, Glioblastoma, Adult
- Trial name
- CAPTEM (NCT03213002)
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Northwell Health
Brain and Central Nervous System Tumors
Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with autologous bone marrow transplantation or…
- Trial name
- NCT00003101
- Testing
- filgrastim, busulfan, lomustine
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pediatric Cancer
TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide
Non-randomized, international, multi-centre, open-label, single arm study to determine the pharmacokinetic (PK) parameters of a single dose of an oral suspension of temozolomide (KIMOZO) in the pediatric population aged 1 year…
- Trial name
- NCT04610736
- Testing
- Temozolomide Oral Suspension
- Where
- 11 sites in France, Germany and 3 more
- Volunteers
- 49 people
- Sponsor
- Orphelia Pharma
Glioblastoma (GBM)
Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial In Patients Scheduled for shOrt Course radiatioN
Patients will receive in addition to standard histology analysis also the PDC- based drug screening.
- Trial name
- ATTRACTION (NCT07627334)
- Testing
- CBmed drug screening platform
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Medical University of Vienna
Ganglioneuroblastoma, Recurrent Neuroblastoma
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
This randomized phase II trial studies how well irinotecan hydrochloride and temozolomide with temsirolimus or dinutuximab work in treating younger patients with neuroblastoma that has returned or does not respond to treatment.
- Trial name
- NCT01767194
- Testing
- Dinutuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 157 sites in United States, Australia and 3 more
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma
Assessment of a Large US EHR Database as Meeting FDA Fit-for-Purpose Requirements to Provide External Controls for Study BPM31510 in Participants With Glioblastoma
Glioblastoma is a rare, aggressive brain tumor that leads to death within 2 years of diagnosis in more than half of patients. There are currently 123 studies ongoing that are testing treatments for glioblastoma.
- Trial name
- NCT07674095
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- BPGbio
Glioblastoma, Dexamethasone
Restrictive Use of Dexamethasone in Glioblastoma
The administration of steroids, most commonly dexamethasone (DEX), has established as standard of care during treatment of glioblastoma (GBM) and is widely used during the entire course of the disease including pre- and…
- Conditions
- Glioblastoma, Dexamethasone, Steroids
- Trial name
- RESDEX (NCT04266977)
- Testing
- Dexamethasone
- Where
- 4 sites in Switzerland
- Volunteers
- 50 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.